{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T20:50:45Z","timestamp":1782852645657,"version":"3.54.5"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T00:00:00Z","timestamp":1595980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T00:00:00Z","timestamp":1595980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      INAD is an autosomal recessive neurogenetic disorder caused by biallelic pathogenic variants in\n                      <jats:italic>PLA2G6<\/jats:italic>\n                      . The downstream enzyme, iPLA\n                      <jats:sub>2<\/jats:sub>\n                      , plays a critical role in cell membrane homeostasis by helping to regulate levels of phospholipids. The clinical presentation occurs between 6\u2009months and 3\u2009years with global developmental regression, hypotonia, and progressive spastic tetraparesis. Progression is often rapid, resulting in severe spasticity, visual impairment, and cognitive decline, with many children not surviving past the first decade of life. To date, no accepted tool for assessing the severity of INAD exists; other commonly used scales (e.g. CHOP-INTEND, Modified Ashworth, Hammersmith Functional Motor Scale) do not accurately gauge the current severity of INAD, nor are they sensitive\/specific enough to monitor disease progression. Finally, these other scales are not appropriate, because they do not address the combination of CNS, peripheral nerve, and visual pathology that occurs in children with INAD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We have developed and validated a structured neurological examination for INAD (scored out of 80). The examination includes six main categories of pediatric developmental evaluation: 1) gross motor-and-truncal-stability skills, 2) fine motor skills, 3) bulbar function, 4) ocular function, 5) temporo-frontal function, and, 6) Functional evaluation of the autonomic nervous system. A cohort of patients diagnosed with INAD were followed prospectively to validate the score against disease severity and disease progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We show significant correlation between the total neurological assessment score and months since symptom onset with a statistically significant (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20096.7\u2009\u00d7\u200910\n                      <jats:sup>\u2212\u200907<\/jats:sup>\n                      ) correlation between assessment score and disease onset. As hypothesized, the coefficient of months-since-symptom-onset is strongly negative, indicating a negative correlation between total score and months since symptom onset.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We have developed and validated a novel neurological assessment score in INAD that demonstrates strong correlation with disease severity and disease progression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-020-01479-5","type":"journal-article","created":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T09:05:10Z","timestamp":1596013510000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The infantile neuroaxonal dystrophy rating scale (INAD-RS)"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8515-744X","authenticated-orcid":false,"given":"Paldeep S.","family":"Atwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Midei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darius","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Fay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Heerinckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Milner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,29]]},"reference":[{"key":"1479_CR1","doi-asserted-by":"publisher","first-page":"109068","DOI":"10.1016\/j.biopha.2019.109068","volume":"118","author":"ZB Wang","year":"2019","unstructured":"Wang ZB, Liu JY, Xu XJ, Mao XY, Zhang W, Zhou HH, et al. Neurodegeneration with brain iron accumulation: insights into the mitochondria dysregulation. Biomed Pharmacother. 2019;118:109068.","journal-title":"Biomed Pharmacother"},{"key":"1479_CR2","doi-asserted-by":"crossref","unstructured":"Adams D, Midei M, Dastgir J, Flora C, Molinari RJ, Heerinckx F, et al. Treatment of infantile neuroaxonal dystrophy with RT001: a di-deuterated ethyl ester of linoleic acid: report of two cases. JIMD Rep. 2020;54(1):54\u201360.","DOI":"10.1002\/jmd2.12116"},{"issue":"5","key":"1479_CR3","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1086\/508572","volume":"79","author":"S Khateeb","year":"2006","unstructured":"Khateeb S, Flusser H, Ofir R, Shelef I, Narkis G, Vardi G, et al. PLA2G6 mutation underlies infantile neuroaxonal dystrophy. Am J Hum Genet. 2006;79(5):942\u20138.","journal-title":"Am J Hum Genet"},{"issue":"18","key":"1479_CR4","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1212\/01.wnl.0000310986.48286.8e","volume":"70","author":"M Kurian","year":"2008","unstructured":"Kurian M, Morgan N, MacPherson L, Foster K, Peake D, Gupta R, et al. Phenotypic spectrum of neurodegeneration associated with mutations in the PLA2G6 gene (PLAN). Neurology. 2008;70(18):1623\u20139.","journal-title":"Neurology"},{"key":"1479_CR5","volume-title":"PLA2G6-associated neurodegeneration. GeneReviews\u00ae","author":"A Gregory","year":"2017","unstructured":"Gregory A, Kurian MA, Maher ER, Hogarth P, Hayflick SJ. PLA2G6-associated neurodegeneration. GeneReviews\u00ae. Seattle: University of Washington; 2017."},{"issue":"18","key":"1479_CR6","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1212\/01.wnl.0000327094.67726.28","volume":"71","author":"A Gregory","year":"2008","unstructured":"Gregory A, Westaway S, Holm IE, Kotzbauer P, Hogarth P, Sonek S, et al. Neurodegeneration associated with genetic defects in phospholipase A2. Neurology. 2008;71(18):1402\u20139.","journal-title":"Neurology"},{"issue":"2","key":"1479_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1136\/jmg.2008.061929","volume":"46","author":"A Gregory","year":"2009","unstructured":"Gregory A, Polster BJ, Hayflick SJ. Clinical and genetic delineation of neurodegeneration with brain iron accumulation. J Med Genet. 2009;46(2):73\u201380.","journal-title":"J Med Genet"},{"issue":"6","key":"1479_CR8","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.ejpn.2008.01.005","volume":"12","author":"I Carrilho","year":"2008","unstructured":"Carrilho I, Santos M, Guimar\u00e3es A, Teixeira J, Chor\u00e3o R, Martins M, et al. Infantile neuroaxonal dystrophy: what\u2019s most important for the diagnosis? Eur J Paediatr Neurol. 2008;12(6):491\u2013500.","journal-title":"Eur J Paediatr Neurol"},{"issue":"2","key":"1479_CR9","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1468-1331.2008.02397.x","volume":"16","author":"Y Wu","year":"2009","unstructured":"Wu Y, Jiang Y, Gao Z, Wang J, Yuan Y, Xiong H, et al. Clinical study and PLA2G6 mutation screening analysis in Chinese patients with infantile neuroaxonal dystrophy. Eur J Neurol. 2009;16(2):240\u20135.","journal-title":"Eur J Neurol"},{"issue":"5","key":"1479_CR10","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/j.1399-0004.2010.01417.x","volume":"78","author":"A Tonelli","year":"2010","unstructured":"Tonelli A, Romaniello R, Grasso R, Cavallini A, Righini A, Bresolin N, et al. Novel splice-site mutations and a large intragenic deletion in PLA2G6 associated with a severe and rapidly progressive form of infantile neuroaxonal dystrophy. Clin Genet. 2010;78(5):432\u201340.","journal-title":"Clin Genet"},{"issue":"1","key":"1479_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13023-020-01355-2","volume":"15","author":"FD Altuame","year":"2020","unstructured":"Altuame FD, Foskett G, Atwal PS, Endemann S, Midei M, Milner P, et al. The natural history of infantile neuroaxonal dystrophy. Orphanet J Rare Dis. 2020;15(1):109.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1479_CR12","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jval.2016.11.005","volume":"20","author":"JH Powers 3rd","year":"2017","unstructured":"Powers JH 3rd, Patrick DL, Walton MK, Marquis P, Cano S, Hobart J, et al. Clinician-reported outcome assessments of treatment benefit: report of the ISPOR clinical outcome assessment emerging good practices task force. Value Health. 2017;20(1):2\u201314.","journal-title":"Value Health"},{"issue":"4","key":"1479_CR13","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.ajhg.2018.02.018","volume":"102","author":"PR Blackburn","year":"2018","unstructured":"Blackburn PR, Xu Z, Tumelty KE, Zhao RW, Monis WJ, Harris KG, et al. Bi-allelic alterations in AEBP1 Lead to defective collagen assembly and connective tissue structure resulting in a variant of Ehlers-Danlos syndrome. Am J Hum Genet. 2018;102(4):696\u2013705.","journal-title":"Am J Hum Genet"},{"issue":"4","key":"1479_CR14","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ajmg.a.37491","volume":"170","author":"PS Atwal","year":"2016","unstructured":"Atwal PS, Blease S, Braxton A, Graves J, He W, Person R, et al. Novel X-linked syndrome of cardiac valvulopathy, keloid scarring, and reduced joint mobility due to filamin A substitution G1576R. Am J Med Genet A. 2016;170(4):891\u20135.","journal-title":"Am J Med Genet A"},{"issue":"1","key":"1479_CR15","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10689-018-0086-2","volume":"18","author":"SK Macklin","year":"2019","unstructured":"Macklin SK, Jackson JL, Atwal PS, Hines SL. Physician interpretation of variants of uncertain significance. Familial Cancer. 2019;18(1):121\u20136.","journal-title":"Familial Cancer"},{"issue":"7","key":"1479_CR16","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1681\/ASN.2017111179","volume":"29","author":"M Reichold","year":"2018","unstructured":"Reichold M, Klootwijk ED, Reinders J, Otto EA, Milani M, Broeker C, et al. Glycine Amidinotransferase (GATM), renal Fanconi syndrome, and kidney failure. J Am Soc Nephrol. 2018;29(7):1849\u201358.","journal-title":"J Am Soc Nephrol"},{"key":"1479_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ymgmr.2017.12.005","volume":"15","author":"AN Mohammad","year":"2018","unstructured":"Mohammad AN, Bruno KA, Hines S, Atwal PS. Type 1 sialidosis presenting with ataxia, seizures and myoclonus with no visual involvement. Mol Genet Metab Rep. 2018;15:11\u20134.","journal-title":"Mol Genet Metab Rep"},{"key":"1479_CR18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ymgmr.2016.07.007","volume":"8","author":"TR Donti","year":"2016","unstructured":"Donti TR, Cappuccio G, Hubert L, Neira J, Atwal PS, Miller MJ, et al. Diagnosis of adenylosuccinate lyase deficiency by metabolomic profiling in plasma reveals a phenotypic spectrum. Mol Genet Metab Rep. 2016;8:61\u20136.","journal-title":"Mol Genet Metab Rep"},{"issue":"10","key":"1479_CR19","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1002\/ajmg.a.37187","volume":"167","author":"D Darcy","year":"2015","unstructured":"Darcy D, Atwal PS, Angell C, Gadi I, Wallerstein R. Mosaic paternal genome-wide uniparental isodisomy with Down syndrome. Am J Med Genet A. 2015;167(10):2463\u20139.","journal-title":"Am J Med Genet A"},{"key":"1479_CR20","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ymgmr.2016.11.002","volume":"9","author":"K Sunde","year":"2016","unstructured":"Sunde K, Blackburn PR, Cheema A, Gass J, Jackson J, Macklin S, et al. Case report: 5 year follow-up of adult late-onset mitochondrial encephalomyopathy with lactic acid and stroke-like episodes (MELAS). Mol Genet Metab Rep. 2016;9:94\u20137.","journal-title":"Mol Genet Metab Rep"},{"key":"1479_CR21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ymgmr.2016.03.007","volume":"7","author":"TR Donti","year":"2016","unstructured":"Donti TR, Blackburn PR, Atwal PS. Holocarboxylase synthetase deficiency pre and post newborn screening. Mol Genet Metab Rep. 2016;7:40\u20134.","journal-title":"Mol Genet Metab Rep"},{"issue":"10","key":"1479_CR22","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1002\/humu.23047","volume":"37","author":"PR Blackburn","year":"2016","unstructured":"Blackburn PR, Hickey RD, Nace RA, Giama NH, Kraft DL, Bordner AJ, et al. Silent Tyrosinemia type I without elevated tyrosine or Succinylacetone associated with liver cirrhosis and hepatocellular carcinoma. Hum Mutat. 2016;37(10):1097\u2013105.","journal-title":"Hum Mutat"},{"issue":"9","key":"1479_CR23","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/gim.2014.10","volume":"16","author":"PS Atwal","year":"2014","unstructured":"Atwal PS, Brennan M-L, Cox R, Niaki M, Platt J, Homeyer M, et al. Clinical whole-exome sequencing: are we there yet? Genet Med. 2014;16(9):717\u20139.","journal-title":"Genet Med"},{"key":"1479_CR24","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/8904_2013_282","volume":"14","author":"P Atwal","year":"2013","unstructured":"Atwal P. Mutations in the complex III assembly factor tetratricopeptide 19 gene TTC19 are a rare cause of Leigh syndrome. JIMD Rep. 2013;14:43\u20135 Springer, Berlin, Heidelberg.","journal-title":"JIMD Rep"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01479-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-020-01479-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01479-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T19:22:49Z","timestamp":1627500169000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-020-01479-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,29]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1479"],"URL":"https:\/\/doi.org\/10.1186\/s13023-020-01479-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-25074\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-25074\/v2","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,29]]},"assertion":[{"value":"24 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An IRB-approved written informed consent was obtained from all patients and their parents enrolled in this study. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declarations of 1975, as revised in 2000 [\n                      \n                      ].","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"An IRB-approved written informed consent was obtained from all patients and their parents enrolled in this study with respect to publication. All subjects reported in this manuscript have provided consent for publication, although the reports are anonymous and does not contain personal information. Proof of informed consent is available upon request.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Paldeep S. Atwal, Mark Midei, Frederic Heerinckx, Peter Milner, are employed by, and hold stock in Retrotope, Inc. All other authors have no potential conflicts of interest. All authors confirm that the content of the article has not been influenced by the sponsor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"195"}}